Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination

doi:10.19803/j.1672-8629.20230216

Abstract

Abstract: Objective To explore the entry point of clinical pharmacists to carry out pharmaceutical care for critically ill patients and prevent serious adverse reactions through the introduction of a case of a patient with heart failure complicated with pulmonary infection induced by multi-drug tip torsion ventricular tachycardia. Methods Clinical pharmacists participated in the treatment of a case of malignant arrhythmia caused by multi-drug combination, assisted doctors in identifying suspicious drugs, dealing with drug-induced TdP and implementing pharmaceutical care. Results Clinical pharmacists assisted physicians to adjust the medication regimen and take effective measures for serious adverse reactions, which achieved good results. Conclusion Clinical pharmacists can effectively ensure the safety of medication by participating in the treatment team, taking pharmacy as the breakthrough point and acting as the assistant of doctors.

Key words: torsade de pointes(TdP), prolonged QT interval, pharmaceutical care, adverse drug reaction, multidrug combination

CLC Number:

R994.11

ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.

References

[1] CAO KJ, CHEN KP, CHEN ML, et al.Chinese expert consensus on ventricular arrhythmias[J]. Chinese Journal of Cardiac Pacing and Electrophysiology(中国心脏起搏与心电生理杂志), 2020, 34(3):189-253.
[2] Chinese Society of Cardiology. Expert consensus on emergency management of cardiac arrhythmias[J]. Chinese Journal of Cardiology(中华心血管病杂志), 2013, 41(5): 363-376.
[3] DREW BJ, ACKERMAN MJ, FUNK M, et al.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation[J]. J Am Coll Cardiol, 2010, 55(9): 934-947.
[4] WOOSLEY RL,HEISE CW, GALLOT ET, et al. QTdrugs list [EB/OL]. (2014-08-01)[2023-02-23]. http://www.crediblemeds.org.
[5] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimatingthe probability of adverse drug reactions[J]. Clin Pharmacol Ther,1981,30(2): 239-245.
[6] JIANG WP.Guidelines for the use of amiodarone in antiarrhythmic therapy (2008)[J]. Chinese Journal of Cardiac Pacing and Electrophysiology(中国心脏起搏与心电生理杂志), 2008,22(5):377-385.
[7] TISDALE JE, CHUNG MK, CAMPBELL KB,et al.Drug-induced arrhythmias: a scientific statement from the american heart association[J]. Circulation, 2020, 142(15): 214-233.
[8] LI L,WEN J, FANG DM, et al.A systematic retrospective analysis of quinolones -induced extension of QT interval[J]. Tianjin Pharmacology(天津药学), 2019, 31(2): 15-21.
[9] WANG L, ZHANG L, ZHU L, et al.Research progress of osimertinib-related cardiotoxicity[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志),2023, 43(13): 1516-1520.
[10] DE MARINIS F,WU YL,DE CASTRO G JR,et al. ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positivenon-small-cell lung cancer[J]. Future Oncol, 2019, 15(26): 3003-3014.
[11] PATEL SR, BROWN SN, KUBUSEK JE, et al.Osimertinib-induced cardiomyopathy[J].JACC Case Rep, 2020, 2(4): 641-645.
[12] TISDALE JE, JAYNES HA, KINGERY JR, et al.Development andvalidation of a risk score to predict QT interval prolongation inhospitalized patients[J]. Circ Cardiovasc Qual Outcomes, 2013, 6(4): 479-487.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.